Home NEWS AND MEDIA

NEWS AND MEDIA

Oct 2025

Clinical | NeuExcell's Pioneering In Situ Conversion Therapy to Debut First-In-Class Clinical Trial Results at ESMO Asia 2025

Learn more
Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease

Learn more
Jun 2025

NeuExcell Therapeutics' NXL-004 Gene Therapy Shows Positive Early Results in Treating Recurrent Malignant Glioblastoma

Learn more
Mar 2025

NeuExcell Therapeutics Initiates First-in-Human Clinical Trial of NXL-001 to Treat Alzheimer's Disease

Learn more
Mar 2024

NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy

Learn more